Étiquette : cannabinoides synthetiques

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review, Laura Orsolini et al., 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti  and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]

Lire la suite

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins, Samuel D. Banister and Mark Connor, 2018

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins Samuel D. Banister and Mark Connor Handbook of Experimental Pharmacology, # Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/164_2018_143   Contents 1 Introduction 2 Chemical Classification of Synthetic Cannabinoid Receptor Agonists 3 Cannabinoid Type 1 Receptor (CB1) Structure and Function 4 Historical Synthetic Cannabinoid Receptor Agonists 4.1 Classical Cannabinoids and Phytocannabinoid Analogs 4.2 Nonclassical Cannabinoids 4.3 Aminoalkylindoles (AAIs) 5 Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances 5.1 Molecular Hybridization 5.2 Bioisosteric Fluorination 6 Conclusions References Abstract Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs [...]

Lire la suite

Cannabinoids and Neurogenesis : The Promised Solution for Neurodegeneration ?, Andrea Valeri and Emanuela Mazzon, 2021

Cannabinoids and Neurogenesis : The Promised Solution for Neurodegeneration ? Andrea Valeri and Emanuela Mazzon Molecules, 2021, 26, 6313, 1-26. doi : 10.3390/molecules26206313   Abstract : The concept of neurons as irreplaceable cells does not hold true today. Experiments and evidence of neurogenesis, also, in the adult brain give hope that some compounds or drugs can enhance this process, helping to reverse the outcomes of diseases or traumas that once were thought to be everlasting. Cannabinoids, both from natural and artificial origins, already proved to have several beneficial effects (e.g., anti-inflammatory, anti-oxidants and analgesic action), but also capacity to increase neuronal population, by replacing the [...]

Lire la suite

Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications, Arianna Giorgetti et al., 2021

Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications Arianna Giorgetti, Jennifer P. Pascali, Paolo Fais, Guido Pelletti, Andrea Gabbin, Giorgia Franchetti, Giovanni Cecchetto  and Guido Viel Life, 2021, 11, 440, 1-17. doi : 10.3390/life11050440   Abstract : Novel psychoactive substances (NPS) represent a severe health risk for drug users. Even though the phenomenon has been growing since the early 2000s, the mechanisms of action of NPS at the receptors and beyond them are still scarcely understood. The aim of the present study was to provide a systematic review of the updated knowledge regarding the molecular [...]

Lire la suite

Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin and glutamate systems, William E. Fantegrossi et al., 2018

Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin and glutamate systems William E. Fantegrossi, Cathryn D. Wilson, and Michael D. Berquist III Drug Metabolism Reviews, 2018, 50, (1), 65–73. doi : 10.1080/03602532.2018.1428343 Abstract An association between marijuana use and schizophrenia has been noted for decades, and the recent emergence of high-efficacy synthetic cannabinoids (SCBs) as drugs of abuse has lead to a growing number of clinical reports of persistent psychotic effects in users of these substances. The mechanisms underlying SCB-elicited pro-psychotic effects is unknown, but given the ubiquitous neuromodulatory functions of the endocannabinoid system, it seems likely that agonist actions at cannabinoid type-1 [...]

Lire la suite

Les nouveaux produits de synthèse, MILDECA, 2015

Les nouveaux produits de synthèse Publié le 10/08/2015 https://www.drogues.gouv.fr/comprendre/ce-qu-il-faut-savoir-sur/les-nouveaux-produits-de-synthese Les « nouveaux produits de synthèse » couramment appelés ainsi, portent officiellement le nom de « nouvelles substances psychoactives » (ONU et Union Européenne) car derrière cette appellation existent des substances psychoactives à la fois d’origine naturelle et synthétique. La plupart sont fabriquées en laboratoire, d’où leur appellation de « nouveaux produits de synthèse », voire, en anglais, de « research chemicals » (RC) ou de « designer drugs ». Certaines imitent les effets du cannabis, d’autres les effets de la cocaïne, de la MDMA / ecstasy ou des amphétamines. La première spécificité d’un certain nombre de ces substances est [...]

Lire la suite

Bibliographie : Cannabinoïdes synthétiques et Néocannabinoïdes, Dr Christian Sueur, GRECC, décembre 2020

Bibliographie : Cannabinoïdes synthétiques et Néocannabinoïdes   Dr Christian Sueur, GRECC, décembre 2020   Définitions et Usages des cannabinoïdes synthétiques : 2 - 6 Toxicologie des cannabinoïdes synthétiques : 7– 12 Cannabinoïdes synthétiques et psychose : 11 - 12 Pharmacologie des cannabinoïdes synthétiques : 13 - 16 Neurophysiologie des cannabinoïdes synthétiques : 17 -18 Analyse des cannabinoïdes synthétiques : 18 - 19 Usage médical des cannabinoïdes synthétiques : 20 – 22 Rimonabant : 21 -22  

Lire la suite

Synthetic Pot : Not Your Grandfather’s Marijuana, Benjamin M. Ford et al, 2017

Synthetic Pot : Not Your Grandfather’s Marijuana Benjamin M. Ford, Sherrica Tai, William E. Fantegrossi, and Paul L. Prather Trends in Pharmacological Sciences, 2017, 38, (3), 257–276. doi : 10.1016/j.tips.2016.12.003 Abstract In the early 2000’s in Europe and shortly thereafter in the USA, it was reported that “legal” forms of marijuana were being sold under the name K2 and/or Spice. Active ingredients in K2/Spice products were determined to be synthetic cannabinoids (SCBs), producing psychotropic actions via CB1 cannabinoid receptors, similar to those of Δ9-THC, the primary active constituent in marijuana. Often abused by adolescents and military personnel to elude detection in drug tests due to [...]

Lire la suite

Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective, Koby Cohen and Aviv M. Weinstein, 2018

Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective Koby Cohen and Aviv M. Weinstein Frontiers in Public Health, 2018, Volume 6 | Article 162 doi : 10.3389/fpubh.2018.00162 There is a growing use of novel psychoactive substances containing synthetic cannabinoids. Synthetic cannabinoid products have effects similar to those of natural cannabis, yet, these drugs are more potent and dangerous, and have been associated with dangerous adverse effects. Here, we review current literature on the epidemiology, acute, and chronic effects of synthetic and natural cannabinoid-based drugs. Synthetic drugs contain a mixture of psychoactive compounds that mostly bind cannabinoid receptors with [...]

Lire la suite

Synthetic cannabinoids and potential cardiac arrhythmia risk : an important message for drug users, Jules C. Hancox et al, 2020

Synthetic cannabinoids and potential cardiac arrhythmia risk : an important message for drug users Jules C. Hancox, Nicola J. Kalk and Graeme Henderson Therapeutic Advances in Drug Safety, 2020, 11, 1-4. Doi : 10.1177/2042098620913416   Δ9-Tetrahydrocannabinol, the psychoactive ingredient in cannabis, and synthetic cannabinoid receptor agonists (SCRAs) activate the CB1 receptor to produce their profound behavioural effects and are widely used as recreational drugs. There is growing evidence that SCRAs, commonly known by the street name Spice or K2 (though there are many others, see: http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids) can produce detrimental cardiovascular effects.(1) Commonly observed cardiotoxic effects of SCRAs include tachycardia, chest pain and hypertension.(1) However, bradycardia and [...]

Lire la suite